Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
IPO Year:
Exchange: NASDAQ
Website: pumabiotechnology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2021 | $11.00 | Neutral → Buy | Citigroup |
| 9/28/2021 | Neutral → Buy | Citigroup | |
| 8/6/2021 | $13.00 → $6.00 | Sector Perform | RBC Capital |
| 8/6/2021 | $9.00 → $8.00 | Sell | Goldman Sachs |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00
Citigroup upgraded Puma Biotechnology from Neutral to Buy
RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously
Goldman Sachs reiterated coverage of Puma Biotechnology with a rating of Sell and set a new price target of $8.00 from $9.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Fastest customizable press release news feed in the world
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on August 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 27,875 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, August 1,
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2025. Unless otherwise stated, all comparisons are for the second quarter 2025 compared to the second quarter 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the second quarter of 2025 was $49.2 million, compared to product revenue, net of $44.4 million in the second quarter of 2024. Product revenue, net in the first six months of 2025 was $92.3 million, compared to $84.6 million in the first six months of 2024. Based on accounting principles generally accepted in th
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 7, 2025, following the release of its second quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on July 1, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, July 1, 2025, a
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, June 1, 2025
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, April 1, 2025 a
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ:PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designed to block human epidermal growth factor receptor 2 (HER2) in order to treat and limit breast cancer metastasis. Under the agreement, Er-Kim is appointed as the distribution partner for NERLYNX in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, and Uzb
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting is currently taking place at the McCormick Place in Chicago, Illinois. The poster is entitled, "CT071: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)." Andrew A. Davis, Assistant Professor at Washington University School of Medicine, presented the poster during Session PO.CT01.01 – First-in-Human Phase I Clinical Trials 1. NCI 10495 is sponsored by the National Cancer Institut
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of
10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
10-Q/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Live Leadership Updates
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor
Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper
GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has appointed Hugh O’Dowd as Director and independent Non-executive Chairman of its Board of Directors. US-based Mr. O’Dowd brings significant experience and a background in the life sciences industry to the ONK Therapeutics’ Board in particular building organizations and commercialization of oncology therapeutics. His experience and strategic insights will be invaluable to ONK as it executes on its growth ambitions, progressing its novel, off-the-shelf, dual-targeted, natural killer (NK) cell therapy platform towards human clinical tri
This live feed shows all institutional transactions in real time.
SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
Live finance-specific insights
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2025. Unless otherwise stated, all comparisons are for the second quarter 2025 compared to the second quarter 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the second quarter of 2025 was $49.2 million, compared to product revenue, net of $44.4 million in the second quarter of 2024. Product revenue, net in the first six months of 2025 was $92.3 million, compared to $84.6 million in the first six months of 2024. Based on accounting principles generally accepted in th
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 7, 2025, following the release of its second quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approx
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma's first commercial product. Product revenue, net in the third quarter of 2024 was $56.1 million, compared to $51.6 million in the third quarter of 2023. Product revenue, net in the first nine months of 2024 was $140.8 million, compared to $149.9 million in the first nine months of 2023. Based on accounting principles generally accepted in the United States (GA
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 7, 2024, following the release of its third quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after complet
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2024. Unless otherwise stated, all comparisons are for the second quarter 2024 compared to the second quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the second quarter of 2024 was $44.4 million, compared to product revenue, net of $51.6 million in the second quarter of 2023. Product revenue, net in the first six months of 2024 was $84.6 million, compared to $98.3 million in the first six months of 2023. Based on accounting principles generally accepted in th
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hou